Steven J. Weintraub
Research Subjects
Research Interests
Steven J. Weintraub has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Scott R. Manson
Division of Urology and The Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO 63110, United States
4 shared publicationsBenjamin E. Deverman
Affiliation Division of Urology and The Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, Missouri, United States of America
3 shared publicationsJacob J. Riehm
Affiliation Division of Urology and The Alvin J. Siteman Cancer Center, Washington University School of Medicine, Saint Louis, Missouri, United States of America
2 shared publicationsSara X. Chen
Division of Hospital Medicine, Department of Medicine, Saint Louis Veterans Affairs Medical Center, Saint Louis, MO, USA
2 shared publications- So Hee Dho
Aging Research Institute, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Republic of Korea
2 shared publications Brian L. Cook
Division of Urology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri 63110
1 shared publication
Latest Publications
- 21 July 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-12
Pyridoxine/pyridoxal-5′-phosphate repletion to improve outcomes of alcohol withdrawal syndrome and promote long-term abstinence: a hypothesis
Pyridoxal-5′-phosphate (PLP) deficiency is highly prevalent among individuals with alcohol use disorder (AUD) [1–5]. Notably, those who suffer the most severe manifestations of alcohol withdrawal s...
- 21 July 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-12
Pyridoxine/pyridoxal-5′-phosphate repletion to improve outcomes of alcohol withdrawal syndrome and promote long-term abstinence: a hypothesis
Pyridoxal-5′-phosphate (PLP) deficiency is highly prevalent among individuals with alcohol use disorder (AUD) [1–5]. Notably, those who suffer the most severe manifestations of alcohol withdrawal s...
- 6 May 2026
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 64  (7) , 626-627
Comment on: a prospective pharmacokinetic study of chlordiazepoxide in patients admitted to an intensive care unit or a high dependency unit after treatment of alcohol withdrawal symptoms
Dear Editor,I read with interest the recent article by Reiter et al. [1]. While the authors provide valuable data highlighting the unpredictability of outcomes of frequent chlordiazepoxide dosing f...
- 6 May 2026
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 64  (7) , 626-627
Comment on: a prospective pharmacokinetic study of chlordiazepoxide in patients admitted to an intensive care unit or a high dependency unit after treatment of alcohol withdrawal symptoms
Dear Editor,I read with interest the recent article by Reiter et al. [1]. While the authors provide valuable data highlighting the unpredictability of outcomes of frequent chlordiazepoxide dosing f...
- 14 January 2026
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41  (8) , 2256-2267
The Enduring Impact of Ghostwriting on the Treatment of Alcohol Withdrawal
Guidelines recommend chlordiazepoxide or diazepam over lorazepam for alcohol withdrawal due to lorazepam’s increased risk of breakthrough symptoms and rebound phenomena, including seizures and delirium. Additionally, diazepam has a shorter time to peak effect than lorazepam, enabling more rapid symptom control and accurate titration to avoid over-sedation. The efficacy of chlordiazepoxide and diazepam for alcohol withdrawal was well established by the mid-1970s, while lorazepam was not approved in the USA until 1977. Despite its inferiority and later approval, lorazepam is the most widely used benzodiazepine for Emergency Department and inpatient alcohol withdrawal management. Therefore, it is notable that the first three studies comparing lorazepam to chlordiazepoxide and diazepam, published in 1983 and 1984, all concluded lorazepam is the “drug of choice.” This conclusion is anomalous, as some lorazepam-treated patients developed seizures or delirium tremens, complications not observed with chlordiazepoxide or diazepam. These adverse outcomes were not disclosed in abstracts or discussions but seemingly intentionally concealed within the text. Evidence reveals these studies were ghostwritten by Wyeth, the pharmaceutical company that originally marketed lorazepam. Wyeth sales representatives likely distributed reprint copies of these deceptive “drug of choice” papers to physicians and physicians-in-training, thereby initiating the widespread reiterative intergenerational use of lorazepam for alcohol withdrawal.
- 14 January 2026
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41  (8) , 2256-2267
The Enduring Impact of Ghostwriting on the Treatment of Alcohol Withdrawal
Guidelines recommend chlordiazepoxide or diazepam over lorazepam for alcohol withdrawal due to lorazepam’s increased risk of breakthrough symptoms and rebound phenomena, including seizures and delirium. Additionally, diazepam has a shorter time to peak effect than lorazepam, enabling more rapid symptom control and accurate titration to avoid over-sedation. The efficacy of chlordiazepoxide and diazepam for alcohol withdrawal was well established by the mid-1970s, while lorazepam was not approved in the USA until 1977. Despite its inferiority and later approval, lorazepam is the most widely used benzodiazepine for Emergency Department and inpatient alcohol withdrawal management. Therefore, it is notable that the first three studies comparing lorazepam to chlordiazepoxide and diazepam, published in 1983 and 1984, all concluded lorazepam is the “drug of choice.” This conclusion is anomalous, as some lorazepam-treated patients developed seizures or delirium tremens, complications not observed with chlordiazepoxide or diazepam. These adverse outcomes were not disclosed in abstracts or discussions but seemingly intentionally concealed within the text. Evidence reveals these studies were ghostwritten by Wyeth, the pharmaceutical company that originally marketed lorazepam. Wyeth sales representatives likely distributed reprint copies of these deceptive “drug of choice” papers to physicians and physicians-in-training, thereby initiating the widespread reiterative intergenerational use of lorazepam for alcohol withdrawal.
- 11 November 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60  (5) , 524-525
Comment on “Comparative Dose Response of Diazepam, Lorazepam, and Phenobarbital for Alcohol Withdrawal in the Emergency Department”
- 11 November 2025
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 60  (5) , 524-525
Comment on “Comparative Dose Response of Diazepam, Lorazepam, and Phenobarbital for Alcohol Withdrawal in the Emergency Department”
- 4 May 2025
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63  (5) , 303-309
Should chlordiazepoxide and diazepam be avoided when treating alcohol withdrawal syndrome in patients with hepatic insufficiency?
Chlordiazepoxide and diazepam are first-line treatments for patients with alcohol withdrawal. However, their use is discouraged in hepatic insufficiency due to concerns that impaired metabolism may prolong their half-lives and those of their active metabolites, increasing the risk of prolonged sedation to an unacceptable level. Findings presented here suggest that chlordiazepoxide has minimal sedative activity-its effect is primarily dependent on its metabolites. Chlordiazepoxide metabolism occurs through hepatic oxidation, so its biotransformation to its metabolites can be markedly delayed in patients with hepatic insufficiency. Because unmetabolized chlordiazepoxide has little activity, this delay may lead to the administration of a considerable cumulative dose before a therapeutic response occurs. This could result in the accumulation of a substantial reservoir of unmetabolized chlordiazepoxide ("dose-stacking"). This reservoir would undergo slow biotransformation to chlordiazepoxide metabolites, even after dosing is discontinued. The chlordiazepoxide metabolite demoxepam has a markedly longer half-life (14-95 h) than chlordiazepoxide (6.6-28 h), which may be further prolonged by hepatic insufficiency. Therefore, if chlordiazepoxide dose-stacking occurs in patients with hepatic insufficiency, demoxepam may also accumulate. This can result in a delayed, profound, and prolonged sedative effect. The major metabolite of diazepam, desmethyldiazepam, is no more sedating than diazepam itself. As a result, the rapid onset sedative effect of diazepam-reaching its peak within 5 min when administered intravenously and within 120 min when administered orally-is unaffected by hepatic insufficiency. This allows accurate titration of diazepam to avoid prolonged sedation, even with compromised liver function. The widely accepted assertion that the increased risk of prolonged sedation when using chlordiazepoxide to treat alcohol withdrawal in patients with hepatic insufficiency is primarily due to the prolonged half-lives of chlordiazepoxide and its metabolites appears incorrect. It primarily results from a delayed onset of action and peak effect, driven by slowed chlordiazepoxide metabolism and the greater activity of its metabolites compared to the parent drug. These factors combine to increase the risk of dose-stacking. Dose-stacking is readily avoided with diazepam use in patients with hepatic insufficiency because its rapid time-to-peak effect is unaffected. Although it has long been recommended that diazepam be avoided for the treatment of alcohol withdrawal in patients with hepatic insufficiency, the findings presented here suggest that it can be used as long as the dosing interval exceeds the time-to-peak effect and the patient is assessed for sedation before each dose-measures incorporated into front-loading and symptom-triggered treatments. In contrast, chlordiazepoxide may cause prolonged sedation in patients with hepatic insufficiency-even with close monitoring-due to unrecognized dose-stacking.
- 4 May 2025
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63  (5) , 303-309
Should chlordiazepoxide and diazepam be avoided when treating alcohol withdrawal syndrome in patients with hepatic insufficiency?
Chlordiazepoxide and diazepam are first-line treatments for patients with alcohol withdrawal. However, their use is discouraged in hepatic insufficiency due to concerns that impaired metabolism may prolong their half-lives and those of their active metabolites, increasing the risk of prolonged sedation to an unacceptable level. Findings presented here suggest that chlordiazepoxide has minimal sedative activity-its effect is primarily dependent on its metabolites. Chlordiazepoxide metabolism occurs through hepatic oxidation, so its biotransformation to its metabolites can be markedly delayed in patients with hepatic insufficiency. Because unmetabolized chlordiazepoxide has little activity, this delay may lead to the administration of a considerable cumulative dose before a therapeutic response occurs. This could result in the accumulation of a substantial reservoir of unmetabolized chlordiazepoxide ("dose-stacking"). This reservoir would undergo slow biotransformation to chlordiazepoxide metabolites, even after dosing is discontinued. The chlordiazepoxide metabolite demoxepam has a markedly longer half-life (14-95 h) than chlordiazepoxide (6.6-28 h), which may be further prolonged by hepatic insufficiency. Therefore, if chlordiazepoxide dose-stacking occurs in patients with hepatic insufficiency, demoxepam may also accumulate. This can result in a delayed, profound, and prolonged sedative effect. The major metabolite of diazepam, desmethyldiazepam, is no more sedating than diazepam itself. As a result, the rapid onset sedative effect of diazepam-reaching its peak within 5 min when administered intravenously and within 120 min when administered orally-is unaffected by hepatic insufficiency. This allows accurate titration of diazepam to avoid prolonged sedation, even with compromised liver function. The widely accepted assertion that the increased risk of prolonged sedation when using chlordiazepoxide to treat alcohol withdrawal in patients with hepatic insufficiency is primarily due to the prolonged half-lives of chlordiazepoxide and its metabolites appears incorrect. It primarily results from a delayed onset of action and peak effect, driven by slowed chlordiazepoxide metabolism and the greater activity of its metabolites compared to the parent drug. These factors combine to increase the risk of dose-stacking. Dose-stacking is readily avoided with diazepam use in patients with hepatic insufficiency because its rapid time-to-peak effect is unaffected. Although it has long been recommended that diazepam be avoided for the treatment of alcohol withdrawal in patients with hepatic insufficiency, the findings presented here suggest that it can be used as long as the dosing interval exceeds the time-to-peak effect and the patient is assessed for sedation before each dose-measures incorporated into front-loading and symptom-triggered treatments. In contrast, chlordiazepoxide may cause prolonged sedation in patients with hepatic insufficiency-even with close monitoring-due to unrecognized dose-stacking.
- 11 February 2020
- Published by Springer Nature in Spinal Cord
- Vol. 58  (5) , 626-629
A potential widespread and important role for sleep-disordered breathing in pressure injury development and delayed healing among those with spinal cord injury
Soft tissue pressure injuries commonly occur in those with spinal cord injury. They add an immeasurable medical, emotional, and social burden to those who suffer a spinal cord injury and ultimately can cause death due to sepsis when they ulcerate and become infected. Hence it is notable that (i) obstructive sleep apnea and other forms of sleep-disordered breathing are highly prevalent among those with spinal cord injury; (ii) several of the pathophysiologic consequences of sleep-disordered breathing, including hypoxemia, ischemia, oxidative stress, and endothelial dysfunction, would be expected to increase susceptibility to pressure injuries, worsen their severity, and slow or prevent their healing; and (iii) there is emerging clinical evidence that sleep-disordered breathing can have a significant role in the pathogenesis of other types of chronic wounds and that treatment of sleep-disordered breathing can aid in the healing of these wounds. These findings raise the possibility that sleep-disordered breathing may have a widespread and important role in the development, severity, and persistence of pressure injuries in those with spinal cord injury and that treatment of sleep-disordered breathing may be an effective adjunct in their prevention and healing. Studies to determine if there is a functional relationship between sleep-disordered breathing and pressure injuries in individuals with spinal cord injury are warranted.
- 11 February 2020
- Published by Springer Nature in Spinal Cord
- Vol. 58  (5) , 626-629
A potential widespread and important role for sleep-disordered breathing in pressure injury development and delayed healing among those with spinal cord injury
Soft tissue pressure injuries commonly occur in those with spinal cord injury. They add an immeasurable medical, emotional, and social burden to those who suffer a spinal cord injury and ultimately can cause death due to sepsis when they ulcerate and become infected. Hence it is notable that (i) obstructive sleep apnea and other forms of sleep-disordered breathing are highly prevalent among those with spinal cord injury; (ii) several of the pathophysiologic consequences of sleep-disordered breathing, including hypoxemia, ischemia, oxidative stress, and endothelial dysfunction, would be expected to increase susceptibility to pressure injuries, worsen their severity, and slow or prevent their healing; and (iii) there is emerging clinical evidence that sleep-disordered breathing can have a significant role in the pathogenesis of other types of chronic wounds and that treatment of sleep-disordered breathing can aid in the healing of these wounds. These findings raise the possibility that sleep-disordered breathing may have a widespread and important role in the development, severity, and persistence of pressure injuries in those with spinal cord injury and that treatment of sleep-disordered breathing may be an effective adjunct in their prevention and healing. Studies to determine if there is a functional relationship between sleep-disordered breathing and pressure injuries in individuals with spinal cord injury are warranted.
- 1 July 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7  (6) , 2087-2088
Possible donor-dependent differences in efficacy of fresh frozen plasma for treatment of ACE inhibitor–induced angioedema
- 1 July 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7  (6) , 2087-2088
Possible donor-dependent differences in efficacy of fresh frozen plasma for treatment of ACE inhibitor–induced angioedema
- 1 July 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1865  (7) , 995-1001
Bcl-xL deamidation is regulated by multiple ion transporters and is intramolecularly catalyzed
- 1 July 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1865  (7) , 995-1001
Bcl-xL deamidation is regulated by multiple ion transporters and is intramolecularly catalyzed
- 18 January 2017
- Published by Springer Nature in CNS Drugs
- Vol. 31  (2) , 87-95
Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal
Benzodiazepines ameliorate or prevent the symptoms and complications of moderate to severe alcohol withdrawal, which can include autonomic hyperactivity, agitation, combativeness, hallucinations, seizures, delirium, and death. The benzodiazepines most commonly used for this purpose are lorazepam, chlordiazepoxide, oxazepam, and diazepam. It is widely asserted that no member of this group is superior to the others for treatment of alcohol withdrawal. However, of these, diazepam has the shortest time to peak effect, which facilitates both rapid control of symptoms and accurate titration to avoid over-sedation. Furthermore, diazepam and its active metabolite, desmethyldiazepam, have the longest elimination half-lives, so their levels decrease in a gradual, self-tapering manner, resulting in a smoother withdrawal, i.e., a lower incidence and severity of both breakthrough symptoms and rebound phenomena, including a possibly decreased seizure risk. Importantly, the fear of increased risk of over-sedation with diazepam compared with other benzodiazepines is based on a misunderstanding of its pharmacokinetics and is unfounded. Similarly, the notion that diazepam should be avoided in patients with liver disease and elderly patients to avoid prolonged over-sedation is based on no more than conjecture. In fact, there is clinical evidence that diazepam is safe for the treatment of alcohol withdrawal in these patients when administered using a simple symptom-based approach. There is one instance in which diazepam should not be used: when intramuscular administration is the only option, the lipophilicity of diazepam can result in slow absorption—either lorazepam or, when rapid control of symptoms is required, midazolam should be used. The comparative pharmacokinetics of the benzodiazepines used in the treatment of alcohol withdrawal together with a comprehensive review of the literature on their use strongly suggest that diazepam should be the preferred benzodiazepine for the treatment of patients experiencing moderate to severe alcohol withdrawal under most circumstances.
- 18 January 2017
- Published by Springer Nature in CNS Drugs
- Vol. 31  (2) , 87-95
Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal
Benzodiazepines ameliorate or prevent the symptoms and complications of moderate to severe alcohol withdrawal, which can include autonomic hyperactivity, agitation, combativeness, hallucinations, seizures, delirium, and death. The benzodiazepines most commonly used for this purpose are lorazepam, chlordiazepoxide, oxazepam, and diazepam. It is widely asserted that no member of this group is superior to the others for treatment of alcohol withdrawal. However, of these, diazepam has the shortest time to peak effect, which facilitates both rapid control of symptoms and accurate titration to avoid over-sedation. Furthermore, diazepam and its active metabolite, desmethyldiazepam, have the longest elimination half-lives, so their levels decrease in a gradual, self-tapering manner, resulting in a smoother withdrawal, i.e., a lower incidence and severity of both breakthrough symptoms and rebound phenomena, including a possibly decreased seizure risk. Importantly, the fear of increased risk of over-sedation with diazepam compared with other benzodiazepines is based on a misunderstanding of its pharmacokinetics and is unfounded. Similarly, the notion that diazepam should be avoided in patients with liver disease and elderly patients to avoid prolonged over-sedation is based on no more than conjecture. In fact, there is clinical evidence that diazepam is safe for the treatment of alcohol withdrawal in these patients when administered using a simple symptom-based approach. There is one instance in which diazepam should not be used: when intramuscular administration is the only option, the lipophilicity of diazepam can result in slow absorption—either lorazepam or, when rapid control of symptoms is required, midazolam should be used. The comparative pharmacokinetics of the benzodiazepines used in the treatment of alcohol withdrawal together with a comprehensive review of the literature on their use strongly suggest that diazepam should be the preferred benzodiazepine for the treatment of patients experiencing moderate to severe alcohol withdrawal under most circumstances.
- Open Access
- 25 June 2013
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 11  (6) , e1001588
Control of Cellular Bcl-xL Levels by Deamidation-Regulated Degradation
The cellular concentration of Bcl-xL is among the most important determinants of treatment response and overall prognosis in a broad range of tumors as well as an important determinant of the cellular response to several forms of tissue injury. We and others have previously shown that human Bcl-xL undergoes deamidation at two asparaginyl residues and that DNA-damaging antineoplastic agents as well as other stimuli can increase the rate of deamidation. Deamidation results in the replacement of asparginyl residues with aspartyl or isoaspartyl residues. Thus deamidation, like phosphorylation, introduces a negative charge into proteins. Here we show that the level of human Bcl-xL is constantly modulated by deamidation because deamidation, like phosphorylation in other proteins, activates a conditional PEST sequence to target Bcl-xL for degradation. Additionally, we show that degradation of deamidated Bcl-xL is mediated at least in part by calpain. Notably, we present sequence and biochemical data that suggest that deamidation has been conserved from the simplest extant metazoans through the human form of Bcl-xL, underscoring its importance in Bcl-xL regulation. Our findings strongly suggest that deamidation-regulated Bcl-xL degradation is an important component of the cellular rheostat that determines susceptibility to DNA-damaging agents and other death stimuli. Cellular levels of the pro-survival protein Bcl-xL are an important determinant of cellular susceptibility to many death stimuli, including most cancer therapies. We previously showed that human Bcl-xL undergoes deamidation – the conversion of two neutral asparaginyl side-chains into negatively charged aspartyl side-chains – a process that occurs spontaneously but is accelerated by the treatment of tumor cells with DNA-damaging agents. Here, we show that deamidation activates a hitherto undetected signal sequence within Bcl-xL that targets it for degradation by a pathway involving the proteolytic enzyme calpain. This increased degradation of Bcl-xL, and the consequent enhanced cellular susceptibility to programmed cell death, may contribute to the ability of DNA-damaging agents to kill tumors. We also demonstrate that deamidation of Bcl-xL has likely been conserved from the simplest metazoans to humans, underscoring the importance of deamidation in the regulation of Bcl-xL.
- 25 June 2013
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 11  (6) , e1001588
Open AccessControl of Cellular Bcl-xL Levels by Deamidation-Regulated Degradation
The cellular concentration of Bcl-xL is among the most important determinants of treatment response and overall prognosis in a broad range of tumors as well as an important determinant of the cellular response to several forms of tissue injury. We and others have previously shown that human Bcl-xL undergoes deamidation at two asparaginyl residues and that DNA-damaging antineoplastic agents as well as other stimuli can increase the rate of deamidation. Deamidation results in the replacement of asparginyl residues with aspartyl or isoaspartyl residues. Thus deamidation, like phosphorylation, introduces a negative charge into proteins. Here we show that the level of human Bcl-xL is constantly modulated by deamidation because deamidation, like phosphorylation in other proteins, activates a conditional PEST sequence to target Bcl-xL for degradation. Additionally, we show that degradation of deamidated Bcl-xL is mediated at least in part by calpain. Notably, we present sequence and biochemical data that suggest that deamidation has been conserved from the simplest extant metazoans through the human form of Bcl-xL, underscoring its importance in Bcl-xL regulation. Our findings strongly suggest that deamidation-regulated Bcl-xL degradation is an important component of the cellular rheostat that determines susceptibility to DNA-damaging agents and other death stimuli. Cellular levels of the pro-survival protein Bcl-xL are an important determinant of cellular susceptibility to many death stimuli, including most cancer therapies. We previously showed that human Bcl-xL undergoes deamidation – the conversion of two neutral asparaginyl side-chains into negatively charged aspartyl side-chains – a process that occurs spontaneously but is accelerated by the treatment of tumor cells with DNA-damaging agents. Here, we show that deamidation activates a hitherto undetected signal sequence within Bcl-xL that targets it for degradation by a pathway involving the proteolytic enzyme calpain. This increased degradation of Bcl-xL, and the consequent enhanced cellular susceptibility to programmed cell death, may contribute to the ability of DNA-damaging agents to kill tumors. We also demonstrate that deamidation of Bcl-xL has likely been conserved from the simplest metazoans to humans, underscoring the importance of deamidation in the regulation of Bcl-xL.